Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI106975

Suppressive effect of secretin upon pancreatic alpha cell function

Fausto Santeusanio, Gerald R. Faloona, and Roger H. Unger

Department of Internal Medicine, The University of Texas (Southwestern) Medical School at Dallas, 75235

Veterans Administration Hospital, Dallas, Texas 75216

Find articles by Santeusanio, F. in: PubMed | Google Scholar

Department of Internal Medicine, The University of Texas (Southwestern) Medical School at Dallas, 75235

Veterans Administration Hospital, Dallas, Texas 75216

Find articles by Faloona, G. in: PubMed | Google Scholar

Department of Internal Medicine, The University of Texas (Southwestern) Medical School at Dallas, 75235

Veterans Administration Hospital, Dallas, Texas 75216

Find articles by Unger, R. in: PubMed | Google Scholar

Published July 1, 1972 - More info

Published in Volume 51, Issue 7 on July 1, 1972
J Clin Invest. 1972;51(7):1743–1749. https://doi.org/10.1172/JCI106975.
© 1972 The American Society for Clinical Investigation
Published July 1, 1972 - Version history
View PDF
Abstract

Highly purified secretin, infused endoportally in five conscious mongrel dogs at a rate of 10 clinical units per min for 20 min, caused a prompt and statistically significant reduction in the pancreaticoduodenal vein level of pancreatic glucagon from a control average of 1130 pg/ml (SEM±312) to a nadir of 492 pg/ml (SEM±194) 15 min later (P < 0.01). During modest hyperglycemia of about 130 mg/100 ml, induced by glucose infusion, the infusion of secretin at the same rate elicited even more dramatic suppression of pancreaticoduodenal glucagon levels to virtually unmeasurable concentrations. At a lower rate of infusion (5 U priming injection followed by 1 U/min for 20 min) significant suppression of glucagon secretion during hyperglycemia was also observed. Stimulation of endogenous secretin release by the intraduodenal administration of 14 mEq of HCl in 10 dogs during intravenous glucose infusion was followed by a decline in pancreaticoduodenal vein glucagon from 130 pg/ml (SEM±34) to a nadir of 99 pg/ml (SEM±32) 5 min later (P < 0.05).

The infusion of secretin at a rate of 10 U/min in alloxan-diabetic dogs was associated with a significant decline in peripheral venous plasma glucagon, from a mean preinfusion level of 272 pg/ml (SEM±39) to a nadir of 128 pg/ml (SEM±22) (P < 0.01).

It was concluded that exogenous secretin in the doses employed in this study is a potent suppressor of glucagon secretion, particularly during hyperglycemia. HCl-stimulated endogenous secretin also suppresses glucagon secretion. The ability of secretin to augment the glucagon-suppressing effect of ingested glucose qualifies it uniquely for a physiologic role as a modifier of the islet cell response to ingested glucose. The fact that it lowers the hyperglucagonemia of alloxan-diabetic dogs suggests that its glucagon-suppressing activity may not be insulin dependent.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1743
page 1743
icon of scanned page 1744
page 1744
icon of scanned page 1745
page 1745
icon of scanned page 1746
page 1746
icon of scanned page 1747
page 1747
icon of scanned page 1748
page 1748
icon of scanned page 1749
page 1749
Version history
  • Version 1 (July 1, 1972): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts